These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35752772)

  • 21. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.
    Fenwick E; Marshall DA; Levy AR; Nichol G
    BMC Health Serv Res; 2006 Apr; 6():52. PubMed ID: 16623946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.
    Eckermann S; Willan AR
    Pharmacoeconomics; 2011 Jul; 29(7):563-77. PubMed ID: 21671686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users.
    O'Flaherty M; Lloyd-Williams F; Capewell S; Boland A; Maden M; Collins B; Bandosz P; Hyseni L; Kypridemos C
    Health Technol Assess; 2021 May; 25(35):1-234. PubMed ID: 34076574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.
    Boyers D; Jia X; Jenkinson D; Mowatt G
    Pharmacoeconomics; 2012 Jun; 30(6):483-95. PubMed ID: 22480381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
    Nicod E
    Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increasing the impact of budget impact analysis: incorporating uncertainty for decision-makers in small markets.
    Hofmeister M; Clement F
    Int J Technol Assess Health Care; 2022 Jan; 38(1):e15. PubMed ID: 35080195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
    Williams I; McIver S; Moore D; Bryan S
    Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of domiciliary non-invasive ventilation in patients with end-stage chronic obstructive pulmonary disease: a systematic review and economic evaluation.
    Dretzke J; Blissett D; Dave C; Mukherjee R; Price M; Bayliss S; Wu X; Jordan R; Jowett S; Turner AM; Moore D
    Health Technol Assess; 2015 Oct; 19(81):1-246. PubMed ID: 26470875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.
    Grimm SE; Strong M; Brennan A; Wailoo AJ
    Pharmacoeconomics; 2017 Dec; 35(12):1287-1296. PubMed ID: 28849538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generalisability in economic evaluation studies in healthcare: a review and case studies.
    Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
    Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries.
    Visintin E; Tinelli M; Kanavos P
    Health Policy; 2019 Feb; 123(2):118-129. PubMed ID: 30227974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
    Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
    Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required.
    McKenna C; Soares M; Claxton K; Bojke L; Griffin S; Palmer S; Spackman E
    Value Health; 2015 Sep; 18(6):865-75. PubMed ID: 26409615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis.
    Bojke L; Manca A; Asaria M; Mahon R; Ren S; Palmer S
    Pharmacoeconomics; 2017 Aug; 35(8):767-776. PubMed ID: 28470594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment.
    Lomas JRS
    Value Health; 2019 Aug; 22(8):898-905. PubMed ID: 31426931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis.
    McDaid C; Griffin S; Weatherly H; Durée K; van der Burgt M; van Hout S; Akers J; Davies RJ; Sculpher M; Westwood M
    Health Technol Assess; 2009 Jan; 13(4):iii-iv, xi-xiv, 1-119, 143-274. PubMed ID: 19103134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study.
    Petersohn S; Grimm SE; Ramaekers BLT; Ten Cate-Hoek AJ; Joore MA
    Value Health; 2021 Jul; 24(7):983-994. PubMed ID: 34243842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How Sensitive is Sensitivity Analysis?: Evaluation of Pharmacoeconomic Submissions in Korea.
    Bae S; Lee J; Bae EY
    Front Pharmacol; 2022; 13():884769. PubMed ID: 35652044
    [No Abstract]   [Full Text] [Related]  

  • 40. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.